Literature DB >> 11245456

Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53.

J N Li1, M Gorospe, F J Chrest, T S Kumaravel, M K Evans, W F Han, E S Pizer.   

Abstract

Fatty acid synthetic metabolism is abnormally elevated in tumor cells, and pharmacological inhibitors of the anabolic enzyme fatty acid synthase (FAS), including the natural product cerulenin and the novel synthetic compound c75, are selective inhibitors of tumor cell growth. We have recently reported that these two FAS inhibitors both produce rapid, potent inhibition of DNA replication and S-phase progression in human cancer cells, as well as apoptotic death. Here we report an additional characterization of the cellular response to FAS inhibition. RKO colon carcinoma cells were selected for study because they undergo little apoptosis within the first 24 h after FAS inhibition. Instead, RKO cells exhibited a biphasic stress response with a transient accumulation in S and G2 at 4 and 8 h that corresponds to a marked reduction in cyclin A- and B1-associated kinase activities, and then by accumulation of p53 and p21 proteins at 16 and 24 h and growth arrest in G1 and G2. The response of RKO cells to FAS inhibition resembled a genotoxic stress response, but DNA damage did not appear to be an important downstream effect of FAS inhibition, because none was detected using the single cell gel electrophoresis assay (comet assay) to assess DNA damage. p53 function is probably important in protecting RKO cells from FAS inhibition because, similar to many other tumor lines, RKO cells expressing a dominant negative mutant p53 gene underwent extensive apoptosis within 24 h after FAS inhibition. Sensitization of cells to FAS inhibitors by the loss of p53 raises the possibility that these agents may be clinically useful against malignancies carrying p53 mutations. Whereas induction of apoptosis appeared related to accumulation of the substrate, malonyl-CoA, after FAS inhibition, the cytostatic effects were independent of malonyl-CoA accumulation and may have resulted from product depletion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245456

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.

Authors:  Abir Mukherjee; Jinhua Wu; Suzanne Barbour; Xianjun Fang
Journal:  J Biol Chem       Date:  2012-06-03       Impact factor: 5.157

Review 2.  The role of p53 in cell metabolism.

Authors:  Xing-ding Zhang; Zheng-hong Qin; Jin Wang
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 3.  Targeting Cancer Metabolism and Current Anti-Cancer Drugs.

Authors:  Witchuda Sukjoi; Jarunya Ngamkham; Paul V Attwood; Sarawut Jitrapakdee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Substrate recognition by the human fatty-acid synthase.

Authors:  Loretha Carlisle-Moore; Chris R Gordon; Carl A Machutta; W Todd Miller; Peter J Tonge
Journal:  J Biol Chem       Date:  2005-10-07       Impact factor: 5.157

5.  Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival.

Authors:  Paul L Nguyen; Jing Ma; Jorge E Chavarro; Matthew L Freedman; Rosina Lis; Giuseppe Fedele; Christopher Fiore; Weiliang Qiu; Michelangelo Fiorentino; Stephen Finn; Kathryn L Penney; Anna Eisenstein; Fredrick R Schumacher; Lorelei A Mucci; Meir J Stampfer; Edward Giovannucci; Massimo Loda
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

Review 6.  The Heterogeneity of Lipid Metabolism in Cancer.

Authors:  Joshua K Park; Nathan J Coffey; Aaron Limoges; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

7.  Cohort study of fatty acid synthase expression and patient survival in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Jeffrey A Meyerhardt; Gregory J Kirkner; Andrew T Chan; Takako Kawasaki; Edward L Giovannucci; Massimo Loda; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

8.  Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas.

Authors:  Stefanie M Ueda; Kai Lee Yap; Ben Davidson; Yuan Tian; Vivek Murthy; Tian-Li Wang; Kala Visvanathan; Francis P Kuhajda; Robert E Bristow; Hui Zhang; Ie-Ming Shih
Journal:  J Oncol       Date:  2010-05-19       Impact factor: 4.375

9.  Fatty acid synthase causes drug resistance by inhibiting TNF-α and ceramide production.

Authors:  Hailan Liu; Xi Wu; Zizheng Dong; Zhiyong Luo; Zhenwen Zhao; Yan Xu; Jian-Ting Zhang
Journal:  J Lipid Res       Date:  2013-01-14       Impact factor: 5.922

10.  p63 promotes cell survival through fatty acid synthase.

Authors:  Venkata Sabbisetti; Arianna Di Napoli; Apryle Seeley; Angela M Amato; Esther O'Regan; Musie Ghebremichael; Massimo Loda; Sabina Signoretti
Journal:  PLoS One       Date:  2009-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.